Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KDM4A | O75164 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.56 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | DHODH | Q02127 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NSD2 | O96028 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL228713 | 1.00 | KDM4E (0.56) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| SCHEMBL27589769 | 0.98 | KDM4E (0.54) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| SCHEMBL29502894 | 0.98 | KDM4E (0.54) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| Hydrochloric Acid SCHEMBL7310592 | 0.98 | KDM4E (0.54) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| Hydrochloric Acid SCHEMBL30819457 | 0.98 | KDM4E (0.54) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| Hydrochloric Acid SCHEMBL7308263 | 0.98 | KDM4E (0.54) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| Hydrazine SCHEMBL27689567 | 0.96 | KDM4E (0.53) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| Formaldehyde SCHEMBL27615678 | 0.96 | KDM4E (0.53) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| Formic Acid SCHEMBL31505507 | 0.93 | RAB9A (0.50) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 | |
| Hydrogen Sulfide SCHEMBL27865628 | 0.91 | LMNA (0.51) | KDM4ERAB9AKDM4AL3MBTL1EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747627-A1 | METHODS AND SYSTEMS FOR PREDICTIVE CLASSIFICATION BY MASS SPECTROMETRY AND TRAINED LARGE SPECTRAL MODELS | Matterworks Inc (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-122036713-A | Quinoline derivative compound and preparation method and application thereof | 东北农业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12559739-B2 | Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260002144-A1 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | UNIV COLUMBIA (US) | 2026-01-01 | — | — | US | disclosed |
| EP-4665840-A1 | METHOD FOR OBTAINING EXTRACELLULAR VESICLES (EVS) DERIVED FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS) AND THEIR USE | UNIWERSYTET JAGIELLONSKI (PL) | 2025-12-24 | — | — | EP | disclosed |
| US-20250290059-A1 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-09-18 | — | — | US | disclosed |
| US-20250282783-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. | 2025-09-11 | — | — | US | disclosed |
| US-20250270533-A1 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2025-08-28 | — | — | US | disclosed |
| US-12351844-B2 | Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-08 | — | — | US | disclosed |
| US-12351845-B2 | Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-07-08 | — | — | US | disclosed |
| US-20230137741-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2023-05-04 | — | — | US | disclosed |
| US-20230133615-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC | 2023-05-04 | — | — | US | disclosed |
| WO-2023077166-A1 | METHODS AND COMPOSITIONS FOR ANALYTE QUANTIFICATION | MATTERWORKS INC (US) | 2023-05-04 | — | — | WO | disclosed |
| EP-4126841-A1 | COMPOUNDS FOR INHIBITION OF FIBROBLAST ACTIVATION PROTEIN | Ustav Organicke Chemie A Biochemie Av Cr, V.v.i. (CZ) | 2023-02-08 | — | — | EP | disclosed |
| WO-2023002045-A1 | FIBROBLAST ACTIVATION PROTEIN INHIBITORS AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-01-26 | — | — | WO | disclosed |
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4090371-A1 | COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY REDIRECTING ENDOGENOUS DEUBIQUITINASES | The Trustees of Columbia University in the City of New York (US) | 2022-11-23 | — | — | EP | disclosed |
| EP-4055014-A1 | PYRROLIDINE AND PIPERIDINE COMPOUNDS | Yuhan Corporation (KR) | 2022-09-14 | — | — | EP | disclosed |
| EP-3946411-A1 | COMPOSITIONS AND METHODS FOR GENETICALLY-ENCODED HIGH VOLTAGE-ACTIVATED CALCIUM CHANNEL BLOCKERS USING ENGINEERED UBIQUITIN LIGASES | The Trustees of Columbia University in the City of New York (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220033493-A1 | COMPOSITIONS AND METHODS FOR GENETICALLY-ENCODED HIGH VOLTAGE-ACTIVATED CALCIUM CHANNEL BLOCKERS USING ENGINEERED UBIQUITIN LIGASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002144-A1 | COMPOSITIONS AND METHODS FOR USING ENGINEERED DEUBIQUITINASES FOR PROBING UBIQUITIN-DEPENDENT CELLULAR PROCESSES | CFTR, UBE2V1, UBAP2 | KDM4E 3237/4885RAB9A 1283/4885KDM4A 2304/4885 |
| US-20250282783-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | USP28, USP25, USP24 | KDM4E 1745/4885RAB9A 2129/4885KDM4A 968/4885 |
| US-12559739-B2 | Compositions and methods for using engineered deubiquitinases for probing ubiquitin-dependent cellular processes | SCN1A, UCHL1, SCN8A | KDM4E 1433/4885RAB9A 727/4885KDM4A 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.